Clinical Data Viridian tumbles on positive data for key eye drug prospect BioPharma DiveThe data did not meet investor expectations, and could bring fierce investor debate on commercial feasibility, according to an analyst.Clinical DataOphthalmologyRead full story pharminent March 31, 2026 (Last updated: March 31, 2026) BioPharma Dive The data did not meet investor expectations, and could bring fierce investor debate on commercial feasibility, according to an analyst. Clinical DataOphthalmologyRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: PepGen Loses Half of Share Price on Mixed Data in Rare Muscle-Wasting DiseaseNext: Biogen Secures ‘Running Start’ in Kidney Disease With $5.6B Apellis Buy Related Stories Clinical Data AstraZeneca, Ionis drug fails big heart disease study in major setback pharminent July 9, 2026 Clinical Data Roche’s KRAS drug tops its rivals in lung cancer trial pharminent July 2, 2026 Clinical Data EAN 2026: Real-world data supports safety and efficacy of AbbVie’s Vyalev in Parkinson’s pharminent July 1, 2026
